Comparative Pharmacology
Head-to-head clinical analysis: DUZALLO versus ZYLOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUZALLO versus ZYLOPRIM.
DUZALLO vs ZYLOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Allopurinol is a xanthine oxidase inhibitor that reduces the production of uric acid by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Adults: 200 mg orally twice daily.
100-300 mg orally once daily, maximum 800 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 hours), allowing twice-daily dosing for steady-state achievement within 2–3 days.
Allopurinol: 1-2 hours; oxypurinol: 18-30 hours (prolonged to 48-72 hours in renal impairment). Clinical context: oxypurinol half-life determines dosing interval; dose adjustment required for CrCl < 20 mL/min.
Primarily renal excretion (approximately 70% as unchanged drug); biliary/fecal excretion accounts for about 20%; the remainder undergoes hepatic metabolism.
Renal: allopurinol ~10% unchanged, oxypurinol ~70% unchanged; total renal elimination ~76% (allopurinol + oxypurinol); fecal/biliary: minor (~12-20% as allopurinol, ~3-5% as oxypurinol).
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor